drugset / Trial / NCT00038870
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes
Withdrawn
M.D. Anderson Cancer Center
Immunex Corporation · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
1. Determine the feasibility of generation of autologous Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia in myeloid blast crisis (CML/BC) derived dendritic cell activated lymphocytes (DC/AL) in poor prognosis patients. 2. Determine the toxicity of autologous leukemia derived dendritic cell activated lymphocytes (DC/AL) in patients with AML or CML/BC. 3. Quantitate circulating immune effector cells in patients after infusion of DC/AL. 4. Record the efficacy of AML or CML/BC derived dendritic cells and activated lymphocytes in promoting and sustaining remission in patients with AML or CML/BC.
Timeline
- Start
- 2001-01-31
- Primary completion
- 2003-01-14
- Completion
- 2003-01-14
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendritic Cell Activated Lymphocyte | Cell therapy | — | — |